生长激素促分泌剂 comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-02-26. Where a claim depends on a specific study, the study is described rather than over-claimed.
The lyophilised solid is normally held at -20 °C or colder, shielded from light and moisture. Stability in that state is measured in years, although shelf life depends on residual water content and the container seal. Once dissolved, the peptide is more fragile: aqueous solutions are commonly kept at 2-8 °C and used within days to weeks, and repeated freeze-thaw cycling is avoided. Strongly acidic or basic conditions accelerate hydrolysis, and prolonged exposure to them can strip the terminal amide.
Purity assessment for this peptide relies mainly on reversed-phase high-performance liquid chromatography. A C18 column with a water-acetonitrile gradient containing trifluoroacetic acid separates the target from truncated sequences and oxidation products. Detection near 214 nm exploits the amide backbone, while the aromatic side chains allow additional monitoring close to 280 nm. Reported purity values depend on the method, so a certificate of analysis carries weight only when gradient, column and integration parameters are given.
Reversed-phase high-performance liquid chromatography is the standard tool for assessing purity. Detection near 214 nanometers captures the peptide backbone, and the resulting chromatogram shows the main peak alongside related impurities. Electrospray ionization mass spectrometry confirms molecular mass and supports sequence verification. Common degradation products include oxidized residues, deamidated forms, and truncated fragments, each appearing as a distinct peak or shoulder in the trace.
Quality claims for research peptides vary widely across suppliers. A certificate of analysis should list purity by chromatography, the mass found by spectrometry, and the analytical conditions used. Independent testing at a third-party laboratory is a common way to check identity and purity, because documents alone cannot confirm what is inside a vial. Purity figures describe the proportion of the target peptide among detected species, and they say nothing about biological activity or sterility.
| Property | Value | Notes |
|---|---|---|
| Primary purity method | Reversed-phase HPLC | C18 column, water-acetonitrile gradient |
| Detection wavelength | 214 nm, optionally 280 nm | Amide backbone and aromatic side chains |
| Identity confirmation | Electrospray ionisation mass spectrometry | Deconvoluted mass compared with theory |
| Storage of solid | -20 °C or lower, dry and dark | Stability depends on residual moisture |
| Storage in solution | 2-8 °C, short term | Freeze-thaw cycling avoided |
Quality control for research-grade ipamorelin is not governed by a single harmonized pharmacopeial monograph, so certificates of analysis vary between suppliers. Common tests include appearance, solubility, water content, peptide content by quantitative amino acid analysis, and residual counterion measurement. Independent verification by an outside laboratory is often used to confirm identity and purity claims. Salt form, counterion content, and residual solvent levels are frequently unspecified, which complicates direct comparison between lots and leaves reproducibility partly unresolved.
Identity and purity assessment of ipamorelin relies mainly on reversed-phase high-performance liquid chromatography with ultraviolet detection near 214 nanometers, a wavelength where the peptide backbone absorbs. Mass confirmation is typically obtained by electrospray ionization mass spectrometry or by liquid chromatography coupled to mass spectrometry, comparing the observed mass with the calculated value. Amino acid analysis and peptide mapping after enzymatic digestion can confirm the sequence. Impurity profiles include deletion peptides, truncated fragments, and oxidation products, reported as relative area percentages.
在机制层面，ipamorelin 与生长激素促分泌受体 1a 型结合，该受体也介导胃饥饿素的多种效应。受体激活后，细胞内信号促进生长激素从垂体前叶释放。由于对促肾上腺皮质激素和皮质醇的刺激较弱，它被视为选择性较高的促分泌剂。这种选择性在动物模型和少量人体研究中被观察到，但人体数据仍然有限。
现有文献多来自小规模、短期的研究，涉及生长激素缺乏、术后肠麻痹等方向。长期使用是否导致受体脱敏，以及重复给药后效应是否衰减，仍属开放问题。不同研究之间的剂量、给药途径和受试者特征差异较大，因此结论外推需谨慎。关于临床获益的确切证据尚不充分，需要更大规模的对照试验来澄清。
Ipamorelin 是一种合成五肽，序列为 Aib-His-D-2-Nal-D-Phe-Lys-NH2，分子式 C38H49N9O5，游离碱分子量约 711.85 g/mol。它属于生长激素促分泌素（GHS）家族，作用靶点是胃饥饿素受体 GHS-R1a。该化合物由诺和诺德的研究团队在二十世纪九十年代末报道，设计目标是提高对生长激素释放的选择性。C 端酰胺化与 N 端 Aib 残基是两个用于抵抗肽酶降解的结构特征。
在 GHS 家族中，早期肽类如 GHRP-6 与 GHRP-2 会同时促进生长激素、皮质醇与催乳素的释放，并明显增加食欲。Ipamorelin 在动物与早期人体研究中表现出对生长激素释放的相对选择性，对上述其他激素的影响较小。这种差异通常归因于受体结合模式与下游信号偏向的不同，而完整的分子解释仍有待补充。需要区分的是，选择性是研究观察中的相对程度，并非绝对界限。
At the cellular level, ipamorelin binds the growth hormone secretagogue receptor, also called the ghrelin receptor. Activation of this receptor on pituitary somatotroph cells triggers a signaling cascade that leads to release of growth hormone into circulation. Because release follows a pulsatile pattern, studies often report peak concentration and total area under the curve rather than a single time point. Selectivity for this receptor is the property most frequently discussed in comparative work.
Compared with older secretagogues such as hexarelin or GHRP-6, ipamorelin shows weaker stimulation of cortisol, prolactin, and appetite in the animal models used for early characterization. Whether that selectivity is preserved across longer human exposures remains an open question, because published clinical data are limited in size and duration. Reported effects on food intake are generally described as modest. The compound is therefore treated in the literature as a relatively selective research tool rather than a fully characterized therapeutic agent.
Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue class of compounds. Researchers at a pharmaceutical company first described it in the 1990s while screening small peptides for growth hormone releasing activity. Its chain contains five amino acid residues, two of which are non-natural building blocks, including 2-aminoisobutyric acid and a naphthylalanine derivative. The molecule was designed to act at the ghrelin receptor while avoiding several effects observed with earlier secretagogues.
== Society and culture == VVMs are made by Zebra Technologies and are derived from their "HEATmarker" products. Zebra holds a patent on the VVM+. Temptime Corporation, which Zebra purchased in 2019, holds multiple patents on HEATmarker; these are cited in the VVM+ patent.
== Effects of media portrayals == The media is indirectly responsible for shaping the public's perceptions of mental illness. Although severely inaccurate portrayals often produce negative effects, there can also be positive outcomes.
Bilirubin in plasma is mostly produced by the destruction of erythrocytes. Heme is metabolized into biliverdin (via heme oxygenase) and then into bilirubin (via biliverdin reductase) inside the macrophages. Bilirubin is then released into the plasma and transported to the liver bound by albumin, since it is insoluble in water in this state. In this state, bilirubin is called unconjugated (despite being bound by albumin). In the liver, unconjugated (indirect) bilirubin is up-taken by the hepatocytes and subsequently conjugated with glucuronic acid (via the enzyme uridine diphosphate–glucuronyl transferase). In this state, bilirubin is soluble in water and it is called conjugated bilirubin. Conjugated (direct) bilirubin is excreted into the bile ducts and enters the duodenum. During its transport to the colon, it is converted into urobilinogen by the bacterial enzyme bilirubin reductase. Most of the urobilinogen is further reduced into stercobilinogen and is excreted through feces (air oxidizes stercobilinogen to stercobilin, which gives feces their characteristic brown color). A lesser amount of urobilinogen is re-absorbed into portal circulation and transferred to the liver. For the most part, this urobilinogen is recycled to conjugated bilirubin and this process closes the enterohepatic circle. There is also an amount of urobilinogen which is not recycled, but rather enters the systemic circulation and subsequently the kidneys, where it is excreted. Air oxidizes urobilinogen into urobilin, which gives urine its characteristic color.
Mass spectrometry is a scientific technique for measuring the mass-to-charge ratio of ions. It is often coupled to chromatographic techniques such as gas- or liquid chromatography and has found widespread adoption in the fields of analytical chemistry and biochemistry where it can be used to identify and characterize small molecules and proteins (proteomics). The large volume of data produced in a typical mass spectrometry experiment requires that computers be used for data storage and processing. Over the years, different manufacturers of mass spectrometers have developed various proprietary data formats for handling such data which makes it difficult for academic scientists to directly manipulate their data. To address this limitation, several open, XML-based data formats have recently been developed by the Trans-Proteomic Pipeline at the Institute for Systems Biology to facilitate data manipulation and innovation in the public sector. These data formats are described here.
Sources: en.wikipedia.org
===== Fixed-dose combinations of antiretroviral medicines ===== Abacavir/dolutegravir/lamivudine (abacavir + dolutegravir + lamivudine) Abacavir/lamivudine (abacavir + lamivudine) Dolutegravir/lamivudine/tenofovir (dolutegravir + lamivudine + tenofovir) Efavirenz/emtricitabine/tenofovir Efavirenz/lamivudine/tenofovir (efavirenz + lamivudine + tenofovir) Emtricitabine/tenofovir (emtricitabine + tenofovir) Lamivudine/zidovudine (lamivudine + zidovudine)
=== Medical and health sciences === Medical use of HPLC typically use mass spectrometer (MS) as the detector, so the technique is called LC-MS or LC-MS/MS for tandem MS, where two types of MS are operated sequentially. When the HPLC instrument is connected to more than one detector, it is called a hyphenated LC system. Pharmaceutical applications are the major users of HPLC, LC-MS and LC-MS/MS. This includes drug development and pharmacology, which is the scientific study of the effects of drugs and chemicals on living organisms, personalized medicine, public health and diagnostics. While urine is the most common medium for analyzing drug concentrations, blood serum is the sample collected for most medical analyses with HPLC. One of the most important roles of LC-MS and LC-MS/MS in the clinical lab is the Newborn Screening (NBS) for metabolic disorders and follow-up diagnostics. The infants' samples come in the shape of dried blood spot (DBS), which is simple to prepare and transport, enabling safe and accessible diagnostics, both locally and globally. Other methods of detection of molecules that are useful for clinical studies have been tested against HPLC, namely immunoassays. In one example of this, competitive protein binding assays (CPBA) and HPLC were compared for sensitivity in detection of vitamin D. Useful for diagnosing vitamin D deficiencies in children, it was found that sensitivity and specificity of this CPBA reached only 40% and 60%, respectively, of the capacity of HPLC. While an expensive tool, the accuracy of HPLC is nearly unparalleled.
==== Criticism ==== David Handelsman has criticized terminology and understanding surrounding AAS in many publications. According to Handelsman, the pharmaceutical industry attempted to dissociate the so-called "androgenic" and "anabolic" effects of AAS in the mid-20th-century in order to create non-masculinizing anabolic agents that would be more suitable for use in women and children. However, this effort was unsuccessful and was abandoned by the 1970s. This was related to the subsequent discovery of a single androgen receptor (AR) mediating the effects of AAS in both muscle and reproductive tissue. In addition, it was related to misinterpretation of flawed animal androgen bioassays that had been employed to distinguish between androgenic or virilizing effects and anabolic or myotrophic effects (i.e., the Hershberger assay involving the unrepresentative levator ani muscle). In actuality, all AAS have essentially similar AR-mediated effects, even if some AAS may vary in potency in certain tissues like skin, hair follicles, and prostate gland based on their susceptibility to 5α-reduction (and associated metabolic amplification, inactivation, or lack thereof). Per Handelsman, the terms "anabolic steroid" and "anabolic–androgenic steroid" are obsolete, meaningless, and falsely distinguish these agents from androgens when there is no physiological basis for such distinction. It has also been noted that the use and distinction of the concepts "anabolic" and "androgenic", as well as the term "anabolic–androgenic steroid", are oxymoronic.
Louis, Missouri; Integrative Technologies for Advancing Scientific Cores ABRF 2014, 23–25 March, Albuquerque, New Mexico; Team Science and Big Data: Cores at the Frontier ABRF 2013, 2–5 March, Palm Springs, California; Tools for the Advancement of Convergence Science ABRF 2012, 17–20 March, Orlando, Florida; Learning From Biomolecules ABRF 2011, 19–22 February, San Antonio, Texas; Technologies to Enable Personalized Medicine ABRF 2010, 20–23 March, Sacramento, California; Translating Basic Research With Advances in Biomolecular Technology ABRF 2009, 7–10 February, Memphis, Tennessee; Application and Optimization of Existing and Emerging Biotechnologies ABRF 2008, 9–12 February, Salt Lake City, Utah; Enabling Technologies in the Life Sciences ABRF 2007, 31 March- 3 April, Tampa, Florida; Creating the Biological Roadmap ABRF 2006, 11–14 February, Long Beach, California; Integrating Science, Tools and Technologies with Systems Biology ABRF 2005, 5–8 February, Savannah, Georgia; BioMolecular Technologies: Discovery to Hypothesis ABRF 2004, 28 February – 2 March, Portland, Oregon; Integrating Technologies in Proteomics and Genomics ABRF 2003, 10–13 February, Denver, Colorado; Translating Biology Using Proteomics and Functional Genomics ABRF 2002, 9–12 March, Austin, Texas; Biomolecular Technologies: Tools for Discovery in Proteomics and Genomics ABRF 2001, 24–27 February, San Diego, CA; The New Biology: Technology for resolving Macromolecular Communications ABRF 2000, 19–22 February, Bellevue, Washington; From Singular to Global Analyses of Biological Systems ABRF 1999, 19–22 March, Durham, North Carolina; Bioinformatics and Biomolecular Technologies: Linking Genomes, Proteomes and Biochemistry ABRF 1998, 21–24 March, San Diego, California; From Genomes to Function – Technical Challenges of the Post-Genome Era ABRF 1997, 9–12 February, Baltimore, Maryland; Techniques at the Genome-Proteome Interface ABRF 1996, 30 March – 2 April, San Francisco, California; Biomolecular Techniques
Xaa-Pro dipeptidase, also known as prolidase, is an enzyme that in humans is encoded by the PEPD gene. Prolidase is an enzyme in humans that plays a crucial role in protein metabolism and collagen recycling through the catalysis of the rate-limiting step in these chemical reactions. This enzyme is coded by the gene PEPD (peptidase D), located on chromosome 19. Serum prolidase activity is also currently being explored as a biomarker for diseases.
Sources: en.wikipedia.org
Results are most often expressed as a percentage of total peak area from a reversed-phase separation. That figure reflects the detection wavelength, gradient and integration choices used by the laboratory. Two valid certificates can therefore quote different values for the same material without either being incorrect.
Chromatography separates components but does not identify them. Mass measurement gives an independent check that the main peak corresponds to the expected molecular mass. Used together, the two techniques detect both impurity load and structural misassignment.
Hydrolysis and oxidation are the main degradation routes in aqueous media. Loss of the C-terminal amide and oxidation of the aromatic residues are commonly reported changes. Cool storage and short working periods limit the extent of both processes.
Keep the powder dry, protected from light, and at minus 20 degrees Celsius or lower. A desiccant and a sealed vial limit moisture uptake. Let the vial reach room temperature before opening to reduce condensation.